Form 4 for ANIP ANI PHARMACEUTICALS INC

Accepted 2021-11-23 00:00:00 ET · period of report 2021-11-19 · accession 0001415889-21-005442 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2021-11-23	2021-11-19	ANIP	Gassert Chad	SVP - CORP. DEV, STRATEGY	A - Grant	—	+383.2K	383.2K	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-11-19	A	A	383,226	—	383,226	I Held by Chali Properties LLC	—	—	(F1) On November 19, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of March 8, 2021 (as amended, supplemented or modified from time to time, the "Merger Agreement"), by and among ANI Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), Novitium Pharma LLC, a Delaware limited liability company ("Novitium"), and the other parties thereto, the Issuer completed its acquisition of Novitium. In accordance with the Merger Agreement, an aggregate of 2,000,000 Company Interests of Novitium held by Chali Properties LLC were converted into 383,226 shares of Common Stock of the Issuer. The issuance of the shares was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended. (F2) The Reporting Person holds voting and dispositive power over the shares held by Chali Properties LLC.